0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV-111.86%PremiumDec 20, 2024Expiry Date2.64Intrinsic Value100Multiplier-3DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
MEI Pharma Stock Discussion
“On October 22, 2024 (the “Closing Date”), MEI Pharma, Inc., a Delaware corporation (the “Company”), and Aardvark Therapeutics, Inc., a Delaware corporation (the “Purchaser”), entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”), pursuant to which the Company sold its rights, title and interest in and to certain assets related to ME-...
Wohooo
NEWS
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
MEI Pharma, Inc. reports positive results from the ongoing Phase 1b study of ME-344 in combination with bevacizumab for relapsed metastatic colorectal cancer. 25% of patients had no disease progression at Week 16, exceeding the threshold to add more patients. The combination was well-tolerated, leading to the...
$Gossamer Bio (GOSS.US)$ $Starry Group (STRY.US)$ $Helbiz (HLBZ.US)$ $MEI Pharma (MEIP.US)$ $Digital Brands Group (DBGI.US)$ $Cosmos Health (COSM.US)$ $COMSovereign (COMS.US)$ $Mirati Therapeutics (MRTX.US)$ $United Parcel Service (UPS.US)$ $Sumo Logic (SUMO.US)$
No comment yet